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ABSTRACT 
 Burn wound healing involves a complex set of overlapping processes in an environment 
conducive to ischemia, inflammation, and infection costing $7.5 billion/year in the US alone, in 
addition to the morbidity and mortality that occur when the burns are extensive. We previously 
showed that insulin, when topically applied to skin excision wounds, accelerates re-
epithelialization, and stimulates angiogenesis. More recently, we developed an alginate sponge 
dressing (ASD) containing insulin encapsulated in PLGA microparticles that provides a sustained 
release of bioactive insulin for >20days in a moist and protective environment. We hypothesized 
that insulin-containing ASD accelerates burn healing and stimulates a more regenerative, less 
scarring, healing. Using a heat-induced burn injury in rats, we show that burns treated with 
dressings containing 0.04mg insulin/cm2, every three days for 9 days, have faster closure, faster 
rate of disintegration of dead tissue, and decreased oxidative stress. In addition, in insulin-treated 
wounds the pattern of neutrophil inflammatory response suggests faster clearing of the burn dead 
tissue. We also observe faster resolution of the pro-inflammatory macrophages. We also found 
that insulin stimulates collagen deposition and maturation with the fibers organized more like a 
basket weave (normal skin) than aligned and crosslinked (scar tissue). In summary, application of 
ASD-containing insulin-loaded PLGA particles on burns every three days stimulates faster and 
more regenerative healing. These results suggest insulin as a potential therapeutic agent in burn 
healing and, because of its long history of safe use in humans, insulin could become one of the 
treatments of choice when repair and regeneration are critical for proper tissue function. 
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INTRODUCTION  
 The American Burn Association has reported that about 486,000 people/year received 
medical treatment for burn injuries over the past ten years [1]. Moreover, inadequate wound 
treatment leads to increased morbidity and impaired quality of life while consuming substantial 
health resources in developed countries [2]. Burns are one of the most devastating forms of soft 
tissue injury and are most commonly caused by exposure to heat, electricity, radiation, chemicals 
and/or friction [3]. The damage may only affect the epidermal layer of the skin (superficial burns), 
penetrate a part of the dermis (deep-partial thickness burns) or completely extend through both 
epidermal and dermal layers (full-thickness burns) [4]. 
 
 During the first 48h post-injury, cardiac output, oxygen consumption, decrease in 
metabolic rate and hyperglycemia associated with impaired glucose tolerance, occur [5, 6–8]. 
These parameters then gradually rise, developing a hyper-metabolic response, until a plateau is 
reached at five days after the burn. This response is most likely initiated by the secretion of several 
regulatory proteins including but not limited to hormones such as catecholamine, glucagon and 
dopamine, cytokines such as IL-1, IL-6 and TNF-α, formation of neutrophil adherence complexes 
and reactive oxygen species, ultimately leading to protein and lipid catabolism [8, 9]. The rise in 
oxygen consumption results from the increased energy requirements by major organs and tissues, 
such as liver and muscle [9]. During this early period, increases in inflammation, accompanied by 
endothelial cell dysfunction and microvascular permeability, result in edema [10]. Furthermore, 
intense metabolic changes associated with hyperglycemia and insulin resistance occur, which are 
common complications of severe burn [11].  
 
 The successful use of insulin on problematic wounds began in the 1930’s with 
improvement in the healing of non-diabetic bed sores upon injections of insulin [12]. The topical 
use of insulin was later proven to effectively heal small, uncomplicated decubitus ulcers [13]. 
Insulin was then subcutaneously injected on scalded rats, and shown to promote faster healing, 
with better and thicker epidermal layer, abundant retia and higher number of cells in S-phase [14]. 
Moreover, local injection of long-acting insulin zinc suspension accelerated skin wound healing 
without major side effects [15]. Insulin administration to hospitalized burn patients also has been 
shown to enhance protein synthesis in the muscle and accelerate the healing process [16]. Although 
a variety of therapeutic agents, including growth factors such as epidermal growth factor (EGF) 
[17] or transforming growth factor beta (TGF-β) [18], hormones [19], simvastatin [20] and 
propranolol [21] have been successfully used in treating patients with burn wounds, the elevated 
costs associated with the production of these molecules discourages their application [22].  
 
 Tissue-engineered wound dressings have gained increasing interest as an approach towards 
more rapid wound healing, while reducing pain and discomfort to the patient. This results in faster 
rehabilitation with less extended hospital stays. Wound dressings should prevent bacterial 
infection and be non-toxic, biodegradable, capable of removing wound exudates and painless on 
both application and removal, while providing a moist environment to the wound area [23, 24]. 
Among the different types of wound dressings, alginates have been used because of their 
hemostatic properties during burn healing [25, 26]. Alginate is a low-cost, linear, unbranched 
polysaccharide, obtained from brown seaweed, comprising different amounts of (1o4)β-D-
mannuronic and α-L-guluronic acid units. It is biocompatible, non-toxic, non-immunogenic, 
biodegradable and can undergo gelation upon addition of divalent ions, such as calcium [24, 26]. 
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 We have recently published a procedure describing encapsulation of human recombinant 
insulin in poly(D, L-lactic-co-glycolic acid) (PLGA) microspheres [27]. Using this system we 
obtained sustained release of insulin in aqueous solution for up to 25 days. In order to achieve an 
effective insulin stabilization and release in the wound tissue, insulin-loaded PLGA microspheres 
were further incorporated into alginate sponge dressings [22]. This resulted in the sustained release 
of insulin, while providing a moist environment and protection to the wounds. Here we show that 
slow release of insulin from PLGA particles in alginate dressings stimulates healing of burn 
wounds and that the healing occurs with less scarring.
MATERIALS AND METHODS 
Reagents: Human recombinant crystalline insulin (hRcI), poly-(ethylene glycol) (PEG) (avg MW 
1450 Da and 10 kDa), poly(vinyl alcohol) (PVA) (avg MW 13−23 kDa), CaCl2, NaCl, NaOH, 
and sodium dodecyl sulfate (SDS) were supplied by Sigma Aldrich (Oakville, Canada). PLGA 
(D,L; 50:50, avg 17 kDa) was obtained from Purac Biomaterials (Lincolnshire, U.S.A.). 
Dichloromethane (DCM) was supplied by Caledon Laboratories (Georgetown, Canada). Protanal 
LF10/60 LS (35−45% guluronic/55−65% mannuronic) was obtained from FMC Biopolymer 
(Philadelphia, U.S.A.). A Micro BCA protein assay kit was obtained through ThermoFisher 
(Ottawa, Canada). Other materials were obtained as follows: Vectashield from Vector Laboratories 
(Burlingame, CA); trichrome stain kit from ScyTek Laboratories (Logan, UT); ketamine, xylazine, 
buprenorphine, from Henry Schein (Melville, NY). 
Microparticle and Alginate Sponge Dressing Preparation: A solid-in-oil-in-water (S/O/W) 
method was used to encapsulate crystalline insulin in PLGA microparticles, then embedded in an
alginate sponge dressing as previously described [22, 27]. Circular alginate sponge dressings 
(ASD) were stored at −20°C until use. Before application, ASDs were sterilized under UV light 
for 20 min each side. 
Burn wound model: Animal studies were approved by the Institutional Animal Care and Use 
Committee (IACUC) of the University of California, Riverside. Female adult Sprague-Dawley rats 
weighing 200-240 g were obtained from the University of California Riverside vivarium and 
housed under a 12 h dark/light cycle in a room with controlled temperature and humidity. Animals 
were supplied with standard rat chow and water ad libitum. Prior to burning, the rats were 
anesthetized with an intraperitoneal dose of 80mg/kg ketamine and 16mg/kg xylazine. The 
analgesic buprenorphine (0.05-0.1mg/kg) was administered right after the burn to prevent post-
burn pain.  Photographs of the wounds were taken using a digital camera at a distance of 4cm and 
wound size was then determined using ImageJ software (NIH, Bethesda, MD) overtime during 
healing until re-epithelialization was achieved. Wound tissues were collected 1h after the burn was 
made and at different time points postburn for tissue analysis. Normal skin was also collected from 
an area distant from the burn. Over the period of the experiment, levels of blood glucose were 
monitored with an electronic glucose meter (Bayer; Tarrytown, USA) and animal weight 
determined using a digital electronic scale (Mettler Toledo; Columbus, USA). Insulin levels in the 
tissues were measured using a commercially available kit (Abcam, Cambridge, MA). Insulin in 
the tissue samples was bound to an immobilized antibody and then conjugated with biotinylated 
insulin antibody that was further bound to HRP-conjugated Streptavidin. A chromogenic substrate 
solution was then added to develop color that was read at 450nm and expressed as μLU/mL.
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Histological procedures: At different time points, tissue was collected for histology by excising 
the wound tissues, including an area of 5 mm around the wound edge. Tissues were fixed in 4% 
paraformaldehyde for 2 h, followed by 1 h incubation with 0.1M glycine/PBS and two incubations 
with 15% and 30% sucrose, for ~6h and overnight, respectively. Tissues were then embedded in 
OCT (Tissue-Tek; Torrance, USA), frozen in a mixture of ethanol/dry ice slush and stored at -
80ºC. Sections were stained with Hematoxylin and Eosin and with a modified Masson’s Trichrome 
stain, as previously described [28]. Sections were visualized using a Nikon Microphot-FXA 
microscope with a Nikon DS-Fi1 digital camera. Collagen stained blue, while keratin showed a 
red color, cytoplasm stained pink and cell nuclei were black. 
 
Second Harmonic Generation (SHG) imaging: Collagen’s intrinsic second harmonic generation 
signal were detected by using an inverted Zeiss LSM 510 NLOMETA laser scanning microscope 
(Carl Zeiss Microscopy, LLC, Thornwood, NY) based on the Axiovert 200M inverted microscope 
equipped with standard illumination systems for transmitted light and epifluorescence detection. 
This microscope was also equipped with an NLO interface for a femtosecond Titanium-Sapphire 
laser excitation source (Chameleon-Ultra, Coherent, Inc., Santa Clara, CA) for multiphoton 
excitation. The Chameleon laser provided femtosecond pulses at a repetition rate of about 80 MHz, 
with the center frequency tunable from 690 to 1040 nm. Images were acquired with a long working 
distance objective (Zeiss, 40X water, N.A. 0.8). The two-photon signals from the sample were epi-
collected and discriminated by the short pass 650 nm dichroic beam splitter. The SHG images 
were collected using a META detection module with signals sampled in a 394-405 nm detection 
range (Oexc = 800 nm). Each image presented in this work is 12 bit, 512 u 512 pixels representing 
225 Pm u 225 Pm field of view. 
 
Immunolabeling procedure: Frozen sections were fixed in 4% paraformaldehyde for 20min, 
rinsed with PBS, incubated in a solution of 0.1 M glycine in PBS for 20min and blocked in 10% 
non-immune serum of the secondary antibody species in PBS containing 0.1 % Triton X-100 for 
30min. Slides were then incubated for 2h at room temperature with the primary antibodies in 1% 
BSA/PBS. The primary antibodies used, and respective dilutions, were the following: 1:200 FITC-
labeled mouse anti-rat D-smooth muscle actin (D-SMA, Sigma-Aldrich, St Louis, MO) and 1:100 
rabbit anti-rat myeloperoxidase (MPO, eBioscience, San Diego, CA). Sections were then washed 
three times with 0.1 % BSA in PBS and incubated with 1:25 goat anti-rabbit or 1:100 goat anti-
mouse dilutions of FITC-labeled, or 1:100 goat anti-rabbit Alexa Fluor 594-labeled secondary 
antibodies (Life Technologies, Grand Island, NY), for 1h at room temperature. After washing, 
sections were mounted in Vectashield containing DAPI (Vector Laboratories, Inc. Berlingame, 
CA). Immunofluorescence was visualized and imaged using a Nikon Microphot-FXA 
fluorescence microscope with a Nikon DS-Fi1 digital camera and Nikon NIS-Elements software 
(Nikon Instruments Inc., Melville, NY). 
 
Flow cytometry assay: Tissues disaggregation and digestion were performed in 4ml of RPMI in 
presence of collagenase Type 1 (Worthington Biochemical Corp., Lakewood,NJ) at 370 C for 45 
min. Dissociated tissues were passed through 2-3 times through an 18 gauge needle and then a 20 
gauge needle. Harvested cells were washed with RPMI. Single cell suspension was obtained by 
straining the homogenate via cell strainers. Single cells were then washed with RPMI and stained 
with CD80, CD 86 (eBioscience, San Diego, CA) and CD 163 (AbD Serotec, Raleigh, NC) for 30 
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min. Cells for isotype controls were obtained from the single cell populations and stained with 
Isotype Control APC, Isotype Control FITC and Isotype Control PE (eBioscience, San Diego, 
CA). Stained cells were washed with RPMI, suspended in FACS buffer and read using FACSAria 
Cell Sorting System (BD Biosciences, San Jose, CA). Analysis of data was performed using 
FLOWJO software (FLOWJO, LLC, Ashland,OR) 
 
Cytokines expression: Burn wound tissues were homogenized as described above. ProcartaPlexTM 
cytokine immunoassay was performed according to the manufacturers’ protocol (eBioscience, 
Carlsbad, CA) using equilibrated protein tissue homogenate. Level of interleukin-10 (IL-10) was 
quantified using a LuminexTM 200 instrument (Millipore, Billerica, MA) by monitoring the 
fluorescence associated with the bead set. 
 
In vivo angiogenesis assay: The hair on the backs of C57BL/6 mice was removed using Nair 
(Madera, CA). The next day, they were injected subcutaneously with either insulin (Humulin, 
Indianapolis,IN) (1μg/15μl saline) or 15μl saline using an insulin syringe. Both insulin and PBS 
were injected in different sites of the back of each mouse every 24 hrs for 4 days. The areas 
surrounding the injection sites were labeled using a permanent marker to ensure that the injections 
were always done at the same site. A possible position-dependent effect was discarded by changing 
the site of insulin and PBS administration from mouse to mouse. Skin samples from the injected 
areas were collected and observed at day 5. Blood vessels were highlighted using ImageJ software 
(NIH, Bethesda, MD). Briefly, the scale for all the images was set using a ruler with known 
distance and ImageJ function Analyze-->Scale. The free hand selection tool was used to trace and 
highlight the blood vessels and the image was saved. The total vessel length was then evaluated 
using the analyze function in ImageJ. 
VE-cadherin expression was quantified by Western-blot. Burn wound tissues were homogenized 
in RIPA buffer as previously described and protein quantified using the DC protein assay kit (Bio-
Rad, Hercules, CA). Equal amounts of protein for each sample were mixed with sample buffer, 
boiled for 5 min, and analyzed using a 10% SDS-PAGE. Following one hour blocking in 5% 
bovine serum albumin (BSA), the immunoblotting was performed by incubating the membrane 
with 1:1000 rabbit anti-mouse VE-cadherin (phosphor Y731) primary antibody (Abcam, 
Cambridge, MA) overnight at 4ºC.  Blots were then washed and incubated with the appropriate 
horseradish peroxidase (HRP)-conjugated goat anti-rabbit secondary antibody, followed by a 5min 
incubation with West Dura extended duration substrate (Pierce Biotechnology, Thermo Fisher 
Scientific Inc., Rockford, IL). Blots were also probed for GAPDH (1:1000, Cell Signaling, Boston, 
MA), a housekeeping protein to evaluate equal loading. Band intensities were quantified with 
Image Lab 5.0 (Bio-Rad, Berkeley, CA) and normalized against the GAPDH control. Results were 
then expressed as fold change relatively to the control. 
 
Determination of the antioxidant status in wounded tissues: Antioxidant enzymes activity was 
detected in the tissue extracts as previously described [29]. Briefly, tissues (40-50 mg) were 
homogenized in a bullet blender for 5min at 4ºC using zirconium oxide beads and 10μl RIPA 
buffer (1% NP-40, 0.1% SDS, 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% sodium 
deoxycholate, 1 mM EDTA) per mg of tissue. The extracts were then centrifuged at 12,000 rpm 
for 15 min, at 4oC. The supernatants were either immediately used or aliquoted and stored at -800C 
for later use. 
 Superoxide dismutase (SOD) activity in the tissues was determined using a commercially 
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available kit (Cayman Chemical, Ann Arbor, USA), according to the manufacturer’s protocol. 
Results were expressed as U/ml of tissue extract, one unit of SOD being defined as the amount of 
enzyme needed to achieve 50% dismutation of the superoxide radical.  
 Hydrogen peroxide (H2O2) levels in the tissues were measured using a commercially 
available kit (Cell Technology Inc., Mountain View, USA). The assay is based on the peroxidase-
catalyzed oxidation by H2O2 of the non-fluorescent substrate 10-acetyl-3,7-dihydroxyphenoxazine 
to a fluorescent resorufin read fluorometrically at 530 nm (excitation)/590 nm (emission) using a 
Victor 2 microplate reader. The amount of H2O2 in the supernatants was calculated from a standard 
curve generated with known concentrations of H2O2.  
 Catalase activity in the tissues was measured using a commercial kit (Cayman Chemical, 
Ann Arbor, USA), according to the manufacturer’s procedure. This assay is based on the 
peroxidase ability of catalase together with methanol to produce formaldehyde in the presence of 
an optimal concentration of H2O2. This formaldehyde was then quantified spectrophotometrically 
at 540 nm using 4-amino-3-hydrazino-5-mercapto-1,2,4-triazole (purpald) as the chromogen. 
Catalase activity was expressed as nmol/min/ml. 
 Glutathione peroxidase (GPx) activity was measured indirectly by a coupled reaction with 
glutathione reductase (GR), using a commercially available kit (Cayman Chemical, Ann Arbor, 
USA). GPx reduces H2O2 to H2O, while producing oxidized glutathione (GSSG) in the process, 
which is then recycled to its reduced state by GR and NADPH. Oxidation of NADPH to NADP+ 
is accompanied by a decrease in absorbance at 340nm. Under rate-limiting conditions of GPx 
activity, the rate of decrease in the absorbance measured at 340nm, read at 1-min interval during 
a total of 5 min in a Victor 2 microplate reader, will be directly proportional to the GPx activity of 
the sample. GPx activity was expressed as nmol/min/ml of tissue extract. 
DNA damage assay: 5-6 mg of wound tissue were collected and homogenized in RIPA buffer, as 
described above. DNA was then extracted using the DNeasy Blood and Tissue kit (Qiagen, 
Chatsworth, CA) according to the manufacturer’s protocol. DNA concentration was measured and 
purity confirmed by determining the OD260/OD280 absorption ratio. The levels of 8-hydroxy-2’-
deoxyguanosine (8-OH-dG), which correlate with the amount of oxidative DNA damage, were 
measured spectrophotometrically at 405nm using a DNA/RNA Oxidative Damage EIA kit 
(Cayman Chemical, Ann Arbor, USA) per the manufacturer’s instructions.  
Lipid peroxidation assay: Thiobarbituric acid reactive substances (TBARS), an indicator of lipid 
peroxidation in the tissues, were measured by using a commercially available kit (Cell Biolabs 
Inc., San Diego, USA). Byproducts of lipid peroxidation, like malondialdehyde (MDA) and 4-
hydroxynonenal (4-HNE), form adducts with TBARS that can be detected fluorometrically at 540 
nm/590 nm excitation/emission. TBARS levels were then calculated from a predetermined MDA 
standard curve. 
Protein nitration assay: Nitrotyrosine levels in the tissue were measured by an enzyme 
immunoassay, using a commercially available kit (Cell Biolabs Inc., San Diego, USA). Briefly, 
tissue samples were incubated with an anti-nitrotyrosine primary antibody, followed by a 
horseradish peroxidase (HRP)-conjugated secondary antibody and enzyme substrate, in an ELISA 
plate. Nitrotyrosine content was then measured spectrophotometrically at 412nm against a 
standard curve prepared from predetermined nitrated BSA standards. 
 
Statistical Analysis: Statistical analysis was performed using GraphPad Prism 5 (GraphPad 
Software, La Jolla, CA). A one-way ANOVA, followed by a pairwise comparison post-test, was 
conducted wherever appropriate. A 95% confidence interval was considered as statistical 
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significant. 
 
 
RESULTS 
 Partial thickness burn wounds were made on the dorsum of anesthetized rats with a 1.5 cm 
diameter brass cylinder heated in a water bath at 80ºC for 2min and pressed against the shaved rat 
skin for 6sec (Fig. 1A-C). Rats were then treated with alginate sponge dressing (ASDs), containing 
either PLGA microparticles loaded with 125μg of insulin or ASD with PLGA microparticles 
without insulin. These 3cm in diameter dressings were placed on top of the burn wounds and 
covered with Tegaderm (3M, London, Canada) to keep the dressing in place over the burn (Fig. 
1D,E). Dressings were replaced every 3 days and wounds cleaned with sterile saline.  
 
Body weight (measured every two days) started from the day insulin dressings were applied 
and lasted until the end of healing process, did not show significant difference between placebo 
and insulin-treated rats (Fig. 1F). We also observed a similar physiological rhythm of changes in 
blood glucose in both insulin and placebo-treated rats; the levels of blood glucose decreased in 
from daytime to nighttime which is normal as it depends on the circadian rhythm. However, there 
was a significant decrease in blood glucose at 4 and 6 hrs after insulin application, suggesting the 
gradual releasing of insulin from the dressing. Because in both groups and all times the blood 
glucose level was higher than 60mg/dl, no hypoglycemia occurred (Fig. 1G).  
 
Insulin levels in the tissue were significantly elevated in the insulin-treated burns as seen 
at 12 hrs and remained significantly elevated at 3 and 6 days post burn (each cycle of treatment), 
suggesting the release of insulin from the ASDs. The insulin level in placebo-treated burns stayed 
low until day 9 when they became elevated (Fig. 1H), suggesting the influx of insulin to aid in the 
later stages of burn healing.  
 
Insulin improves burn wound healing 
 Insulin treatment accelerated the wound healing process only moderately as shown by a 
decrease in wound area when compared to placebo-treated wounds, in particular after day 9; this 
improvement was consistent in all of the rats we tested (Fig. 2A,B). However, histological 
evaluation revealed improved quality of the healing tissue. At 3 days post-burn, insulin treatment 
resulted in early disjunction of the epidermal layer when compared to the placebo-treated burn 
(Fig. 2C-F), suggesting a more rapid clearance of the dead burned tissue. Simultaneously, the 
granulation tissue in the insulin-treated burns was more sparse than the same tissue in the placebo, 
indicating faster disintegration of the collagen fibers (Fig. 2 G,H). To examine the condition of 
the collagen in the burn wounds we performed second harmonic generated imaging and show that 
insulin treatment resulted in faster dismantling of collagen fibers; the fibers in the placebo-treated 
burns appear thicker (Fig. 2I,J). Furthermore, insulin-treated burns showed an earlier increase in 
inflammatory cells (Fig. 2K,L), primarily neutrophils and M1 macrophages, cells important in 
clearance of bacterial load and debris, respectively (Fig. 3A&C).  
 
Effects of insulin treatment on inflammation 
 Inflammation levels in the burn wounds were assessed by quantification of inflammatory 
cells, specifically neutrophils and macrophages, at different time points post-burn. A significant 
increase in the number of neutrophils occurred during the first 12hrs in the insulin-treated wounds 
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whereas neutrophils were not detected at that time in the placebo-treated wounds (Fig. 3A). The 
early recruitment of neutrophils to the site of insulin treated burns suggests a faster immune 
response when compared to placebo-treated burns that, in conjunction to an increase in the M1 
macrophages (Fig. 3C), could be responsible for the more rapid clearance of the dead burned 
tissue. 
 The number of macrophages present in the burn wounds was determined by flow 
cytometry. The schematic of the analysis of macrophages with various markers is shown in Fig. 
3B. Singlet cell population was defined by plotting forward scattered light height (FSC-H) vs FSC 
area [1,2]. The cell population was then defined with markers for M1 (CD80+, CD86+, and CD163 
low) and M2 (CD163+, CD80 low, CD86 low) macrophages. The number of M1 macrophages 
steadily increased over time in the placebo-treated burns and at 12 days post-burn the number of 
M1 (pro-inflammatory) macrophages was about 3X higher than at day 3, suggesting continued 
pro-inflammatory activity in the tissue. In contrast, the number of M1 macrophages initially rose 
faster in insulin-treated, becoming significantly higher by day 6, perhaps to clear the higher 
number of neutrophils. However, by day 9, insulin-treated burns returned to that of the placebo 
and by day 12, insulin treatment had significantly decreased the number of these pro-inflammatory 
cells (Fig. 3B,C). The pattern of M2 macrophages was distinctly different (Fig. 3B,D).  At day 3 
post-burn, the placebo was high and then fell off progressively through day 12.  In contrast, insulin-
treated burns started lower at day 3, decreased through day 9 like the placebo but then increased 
significantly at day 12 post-burn, suggesting that insulin induces a more anti-inflammatory 
environment later in healing that potentially contributes to less scarring. Because insulin stimulates 
an anti-inflammatory environment, we investigated the levels of interleukin-10 (IL-10), an anti-
inflammatory cytokine, which is known to be produced by M2 macrophages [30] as well as 
fibroblasts [31]. We found that, with the exception of day 6, IL-10 was significantly elevated 
throughout healing in insulin-treated burns than was the case with placebo-treated burns (Fig. 4). 
Taken together, these findings suggest that insulin treatment induces a more anti-inflammatory 
environment at a time in which the granulation tissue is developing (9-12 days post-burn; full 
wound closure occurs 22-24 days post-burn), decreasing the late inflammatory response and 
leading to less scarring.  
 
Insulin stimulates angiogenesis in healing of burn wounds 
 The presence of new blood vessels was determined by immunolabeling the tissue sections 
for α-smooth muscle actin (α-SMA), a protein present in the smooth muscle cells of the blood 
vessel walls. We observed approximately a 3-fold increase in the number of newly formed blood 
vessels in insulin-treated wounds (Fig. 5A,B). However, this was not accompanied by changes in 
the average blood vessel width or area (Fig. 5C,D). The pro-angiogenic properties of insulin were 
further confirmed in a C57BL/6 mouse model by subcutaneously injecting insulin under the skin 
for 4 days and collecting the skin tissue to measure angiogenesis and the integrity of the blood 
vessels formed. Results show that insulin induced a 1.9-fold increase in the total blood vessel 
length, compared to placebo (Fig. 5E-G). Similarly, VE-cadherin expression was increased about 
1.7-fold in the presence of insulin (Fig. 5H,I).  
 
Insulin improves collagen deposition and maturation 
 Granulation tissue has collagen as the major component of the extracellular matrix (ECM). 
Collagen scaffold plays an intricate and important role in maintaining the biological and structural 
integrity of the wound tissue where both proper collagen deposition and architectural maturation 
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contribute to the quality of healing. We measured hydroxyproline levels in the burn tissue to 
evaluate the collagen content in the granulation tissue during the course of healing and found that, 
when compared to placebo treatment, insulin treatment stimulates a steady increase in 
hydroxyproline levels after day 3 with a brief decrease at day 12 (Fig. 6A). This suggests that 
insulin stimulates higher deposition of collagen in the wound tissue. Indeed, we found more 
collagen fibers by Masson-trichrome staining (Fig. 6B) and, when using second harmonic imaging 
microcopy, we see that the fibers are thicker and the organization is close to the “basket-weave” 
pattern found in normal skin (Fig. 6C). Therefore, increases in hydroxyproline levels during the 
granulation tissue formation and proper maturation of collagen fibers show that insulin is able to 
improve the quality of the newly formed healed tissue. 
 
Insulin treatment decreases the levels of reactive oxygen species  
 It is known that low levels of oxidative stress are beneficial to wound healing, whereas 
excessive levels are problematic for the healing process. We hypothesized that one of the 
mechanisms by which insulin improves burn healing is by decreasing oxidative stress early post-
burn. Upon injury, NADPH oxidase (NOX), acts as the primary source of superoxide anion    (O2-
.), a highly reactive species that in the presence of superoxide dismutase (SOD) is dismutated to 
hydrogen peroxide (H2O2). H2O2, although less reactive, causes tissue damage upon accumulation 
and hence it is important that it be broken down to H2O and O2 or only H2O by the antioxidant 
enzymes catalase and glutathione peroxidase (GPx), respectively (Fig. 7A). Also, H2O2 in the 
presence of iron can enter the Fenton reaction to give rise to OH.  radicals and HO- anions. 
Furthermore, superoxide anion, in the presence of nitric oxide (NO), produced by nitric oxide 
synthase (NOS), generates peroxinitrite (ONOO-) (Fig. 7A) a very reactive nitric oxide species 
that also causes molecular damage.  We found that insulin treatment causes a decrease in SOD 
activity, and consequently H2O2 levels, during the first three days of healing (Fig. 7B, C), 
suggesting that insulin reduces the levels of superoxide anion generated in response to injury. 
Simultaneously, the levels of catalase and GPx were increased during this same period of time, 
contributing to the decrease in H2O2 levels by breaking it down to H2O and O2 or H2O respectively 
(Fig. 7D, E).  In addition, it is well known that ROS can result in deleterious effects on lipids, 
proteins and DNA (Fig. 7A). Lipid peroxidation, measured by the concentration of 
malondialdehyde (MDA) present in the burn tissues, was similar in both insulin- and placebo-
treated wounds during the first 2 days post burn but decreased suddenly at day 3 in insulin-treated 
burns and then increased gradually over time following the curve for placebo but at a lower level 
(Fig. 8A). Damage to proteins, as indicated by nitrotyrosine (Fig. 8B), displays an abrupt dip at 
day 3 as was seen for MDA but then slowly climbs back up to the value of placebo at day 9.  DNA 
as measured by 8-OH-dG levels (Fig. 8C), on the other hand, showed a small but significant dip 
at days 2-3 in insulin-treated burns but then followed the big drop at day 6 seen in the placebo, all 
the while staying slightly below the placebo. The insulin-induced decrease in oxidative stress this 
early during wound healing has powerful consequences on the subsequent healing processes in 
terms of inflammation, angiogenesis and scar formation. 
 
 
DISCUSSION 
 Burn wounds are one of the leading causes of traumatic injury and death. Survivors are 
frequently faced with physical deformities post-healing, and often suffer from psychological 
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problems. Insulin treatment resulted in an early and significantly elevated influx of neutrophils to 
the burn wound site during the first 12hrs. This early increase can help contain microbial infection 
in the burn wounds and help in the removal of necrotic debris [32–34]. The early influx of the 
neutrophils may also suggests a role in the faster epidermal disjunction noted in the insulin-treated 
burns (Fig. 2A-D). The early disintegration of the necrotic tissue may lead to enhanced and better 
wound healing. The cellular and molecular mechanism(s) involved in insulin-induced early influx 
of neutrophils to the site of burn injury warrants further investigation.  We are currently 
undertaking such studies and expect to report on them in the very near future. 
Increase in M1 macrophages, pro-inflammatory phenotype, in insulin-treated burns 
suggests escalation in the host defense mechanism(s). Initial presence of M1 macrophages has 
been suggested to increase phagocytic activity and protect the tissue from bacterial infection and 
promote the removal of damaged tissue [35]. Furthermore, this increase in M1 macrophages may 
explain the observed early clearance of the damaged granulation tissue in insulin-treated burns. 
M2 macrophages have been shown to possess anti-inflammatory properties and promote 
angiogenesis [36, 37]. Although the percentage of macrophages in the placebo burns at Day 3 was 
higher in comparison to insulin treatment, the M2 macrophages in insulin-treated burns 
significantly increased after Day 6 as compared to the placebo and was significantly higher by day 
12 suggesting a potential role in the less scarring burn healing observed when the burns are treated 
with insulin [38].  
 
 Burn wounds cause excessive inflammation and ROS generation, hence the presence of 
anti-inflammatory cytokines such as IL-10 may help reduce inflammation and consequently scar 
formation. The IL-10 expression profile in both the placebo and insulin treated burns was biphasic 
as previously shown by others in burn healing [39, 40]. Our data show that insulin treatment 
significantly stimulates IL-10 production in both the early and the late phases. This suggests that 
one way insulin improves burn healing is by stimulating IL-10. Although the number of M2 
macrophages, known to produce IL-10 [30], was lower in insulin-treated wounds, the source of 
elevated IL-10 stimulated by insulin could be due to fibroblast production [31] at both day 3 and 
after day 9. Fibroblast stimulation and proliferation has been shown to occur in the presence of 
insulin [41]. This anti-inflammatory cytokine has been shown to inhibit the activation of 
macrophages and the presence of reactive oxygen and nitrogen species [42–45]. The significant 
increase in IL-10 levels beyond day 6 in the insulin-treated burns may indicate its effects on 
collagen deposition and reduced scarring observed in the insulin-treated burn wounds [46–49].  
 
 An effective angiogenesis process brings nutrients and oxygen to the cells in the wound 
tissue, increasing their proliferation and migration [50]. We have shown that insulin has a pro-
angiogenic effect in rats; it increases the density of newly formed microvessels in the healing 
tissue. For better visualization and evaluation of newly formed blood vessels, we used an in vivo 
mouse model with thinner skin. In agreement with our findings in the rat model, we observed an 
increased number of blood vessels after treatment with insulin subcutaneously. An increase in 
development of microvessels can help the tissue regain the state of normoxia from a state of 
hypoxia. Indeed, burn wound tissues have increased hypoxia and diminished oxygenation for a 
prolonged period of time, contributing to impaired healing. Therefore, the increased supply of 
oxygen and nutrients to the burn tissue stimulates better healing.  
 Ac
ce
pte
d M
an
us
c i
pt
© 2015 The Author(s) Archiving permitted only in line with the archiving policy of Portland Press Limited. All other rights reserved.
12 
 
Proper granulation tissue formation and remodeling are important to acquire the desired 
structural integrity post wounding. The very significant levels of hydroxyproline, a major 
component of collagen, in insulin-treated burns past day 6 (Fig. 6A) correlates with the increase 
in collagen production and deposition and basket-weave-like collagen fiber structure during the 
granulation tissue formation observed at day 21 (Fig. 6B), suggesting better tissue integrity.  
 
  Burn tissues are characterized by initially having high levels of oxidative stress as a result 
of increased formation of reactive oxygen species (ROS) that surpasses the cells’ antioxidant 
enzymes’ activity [51]. ROS such as superoxide anion and hydrogen peroxide can further react 
with other molecules and/or ions, forming other ROS, such as peroxynitrite when reacting with 
nitric oxide or hydroxyl radicals via the Fenton reaction, both of which lead to oxidative damage 
to most biomolecules in particular to lipids, proteins and DNA [52].  
 
 Insulin has been characterized as regulating several biological processes [53–55]. In the 
present study, we show that the levels of SOD activity are significantly increased in insulin-treated 
burn wounds shortly after burning. This suggests elevated dismutation of superoxide anions 
resulting in generation of H2O2 which is effectively removed by increased activity of both catalase 
and GPx in insulin-treated burns, resulting in significantly lower levels of H2O2, thereby indicating 
a decrease in oxidative stress.  
 
In conclusion, sustained release of insulin from PLGA microparticles incorporated into 
alginate dressings accelerates wound healing of burns and improves the restoration of tissue 
integrity. This was associated with decreased initial oxidative damage, early recruitment of 
neutrophils, reduced damage to macromolecules and well-controlled inflammation, as well as 
increased angiogenesis and proper collagen deposition and maturation. The result is a completely 
healed tissue after 21 days post burn, with proper tissue organization, indicating that insulin, in 
particular when incorporated in the alginate-PLGA delivery system, may be an improved therapy 
for burn wounds. 
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CLINICAL PERSPECTIVES 
A short outline highlighting the clinical significance of the paper within approximately 100-150 
words (about three sentences) should be provided. This section should (i) provide some 
background as to why the study was undertaken, (ii) provide a brief summary of the results and 
then (iii) indicate the potential significance of the results to human health and disease. 
(i) The study was undertaken to investigate the efficacy of sustained release of insulin 
from PLGA microparticles embedded in alginate gels in burn wound healing and to 
understand the mechanism of the accelerated healing observed in insulin treated 
burns. 
(ii) Our findings show that sustained release of insulin from PLGA microparticles lead to 
accelerated healing via decrease in oxidative stress and tissue damage, early 
recruitment of neutrophils, management of inflammatory cells, enhanced 
angiogenesis, and proper collagen deposition and maturation.  
(iii) Use of sustained release of insulin in a moist environment in burn wounds could 
result in faster and improved healing outcomes. 
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FIGURE LEGENDS   
Figure 1. Partial thickness burn wound model system: (A) Hair was removed from the back of 
Sprague-Dawley rats by use of ‘Nair’. (B) Brass metal at 80˚C was used to create (C) identical 
burns at the shaved site. (D) Insulin-loaded alginate sponge dressing was wetted with 100μl of 
sterile water. (E) Sponge dressing was placed on the site of burn injury and covered with a 
transparent Tegaderm film. Dressing was changed every three days. (F) Change in body weight 
over time was measured every 2 days post-burn. (G) Level of blood glucose was measured using 
an electronic glucose meter every two hours post-burn. (H) Insulin levels in the burn tissue were 
measured using a sandwich ELISA, and the levels were detected at 450nm. All data are Mean ± 
SD. n= 6 **p<0.01,***p<0.001.  
 
Figure 2. Insulin-treated burns show improved healing: (A) Enhanced wound closure was 
observed in insulin-treated rats when compared to the placebo-treated group. Scale bar = 5mm (B) 
Percent wound closure over time was evaluated by tracing wounds using ImageJ. (C-J) 
Histological evaluation of placebo- and insulin-treated burn wound sections at Day 3 post-burn 
was done by staining with Hemotoxylin and Eosin. Insulin-treated burns showed early epidermal 
disjunction (C-F) Scale bar = 100μm, less compact granulation tissue (G,H) Scale bar = 100μm. 
Second harmonic imaging microscopy of burn tissue at Day 3 showed increased fraying of the 
collagen fibrillar structure in insulin-treated burns. (I,J) Scale bar = 10μm. Enhanced recruitment 
of inflammatory cells in insulin-treated burns (K,L) Scale bar = 100μm. All data are Mean ± SD. 
n= 6 **p<0.01,***p<0.001.  
 
Figure 3. Insulin-treated burns show early and improved inflammatory response: (A) Burn 
wound sections were immunolabeled with antibodies against myeloperoxidase (MPO), a 
neutrophil marker. Early induction of neutrophils was seen in insulin-treated burns at 12hrs post 
burn. The number of neutrophils was counted for 10 fields. (B) Schematic of flow cytometry 
analysis of single cells isolated from placebo- and insulin-treated burns at various time points. 
[1,2,3] SSC-A is Side scatter area, FSC-H is Forward scatter Height and FSC-A is Forward scatter 
area. [4] FACS was performed on burn wound cells immunolabeled with CD80- PE, CD86- FITC 
and CD163-APC. [5] Cells that are CD163+, CD80 low and CD86 low are of M2 macrophage 
phenotype. [6] Cells that are CD80+, CD86+ and CD163 low are of M1 macrophage phenotype. 
Percent macrophages calculation shown in [5] and [6] are based on the parent population in [4]. 
(C) Percentage of M1 macrophage phenotype cells were calculated based on the total cell 
population using the markers CD80+, CD86+ and CD163 low (D) Percentage of M2 macrophage 
phenotype cells were calculated based on the total cell population  using  the markers CD80low, 
CD86low and CD163+. All data are Mean ± SD. *p<0.05,**p<0.01. n=5 in 3 different 
experiments. 
 
Figure 4. Interleukin-10 (IL-10) levels are elevated in insulin-treated burns: Burn wound 
tissue homogenate was used to quantify the levels using a cytokine immunoassay. Levels of IL-10 
were quantified using a LuminexTM 200 instrument by monitoring the fluorescence associated 
with the magnetic bead set. All data are Mean ± SD. *p<0.05, **p<0.01,***p<0.001. 
 
Figure 5. Insulin-treated burns show increased angiogenesis and improved permeability of 
blood vessels: (A) Burn wound sections were stained with α smooth muscle actin (αSMA), for 
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pericytes/smooth muscle cells lining blood vessels at Day 9 post burn. (B,C,D) The area and width 
of the blood vessels were calculated using ImageJ. The number of blood vessels was counted for 
10 fields. (E,F, G)  Stimulation of angiogenesis upon insulin treatment was done by subcutaneous 
injection of 1μg insulin and PBS independently for 4 days, followed by excision of the area of 
interest and counting the length of blood vessels. (H, I) Immunoblot analysis and quantification 
of VE cadherin levels was done to support the data in H and I. Data shown are representative of 3 
blots. Figure E-I were done in mice. All data are Mean ± SD. *p<0.05, **p<0.01,***p<0.001.  
 
Figure 6. Collagen deposition is increased and more mature in insulin-treated burns: (A) 
Hydroxyproline estimation, major component of collagen and roles in collagen stability, was done 
by chromogen production that was read at an absorbance maximum at 560 nm. (B) Day 21 post 
burn tissue treated with insulin or placebo were sectioned and stained with Masson trichrome, that 
stains the nuclei dark with Weigert’s hematoxylin, the cytoplasm and muscle fibers red with 
Biebrich scarlet dye, and the collagen blue with analine blue dye. (C) Second harmonic imaging 
microscopy of the burns at Day 21, shows better ‘basket weave’ like structures in insulin-treated 
burn as compared to the placebo-treated group.  Data in A are Mean ± SD. n=5 *p<0.05, 
**p<0.01,***p<0.001 
 
Figure 7. Regulation of redox state is enhanced in insulin-treated burns: (A) Schematic 
representing redox mechanism of production of reactive oxygen species and their detoxification 
by catalase and glutathione peroxidase enzymes. (B) Superoxide dismutase (SOD) activity was 
measured using tetrazolium salt that is detectible at 450nm upon conversion into formazan dye. 
One unit of SOD is defined as the amount of enzyme needed to cause 50% dismutation of the 
superoxide radical. (C) H2O2 was measured using a non-fluorescent substrate 10-acetyl-3,7-
dihydroxyphenoxazine that converts to fluoroscent substance, resofurin, detectible at 
530nm/605nm. (D) Catalase activity was measured spectrophotometrically using chromogen 
purpald at 540nm. Catalase and methanol react to give rise to formaldehyde that further reacts with 
the chromogen. (E) Glutathione peroxidase activity was measured using a kinetic reactive 
measurement where glutathione peroxidase is the limiting reagent. Absorbance was read at 340nm 
at 1min intervals. Overall, oxidative stress was reduced in insulin treated burns. All data are Mean 
± SD. n=5 *p<0.05,**p<0.01,***p<0.001. 
Figure 8. Damage to lipids, proteins and DNA is reduced in insulin-treated burns : (A) Lipid 
peroxidation levels were fluorometrically measured at an Ex/Em of 540nm/590nm using 
thiobarbituric acid reactive substances (TBARS). (B) Nitrotyrosine levels were evaluated using a 
competitive enzyme immunoassay. (C) 8-OHdG levels were read spectrophotometrically at 
412nm using Ellman’s reagent. Damage caused by oxidative stress was ameliorated in the insulin-
treated burns. All data are Mean ± SD. n= 5 *p<0.05,**p<0.01.   
 
SUMMARY STATEMENT 
Bioactive crystalline insulin microencapsulated in a FDA-approved copolymeric substance 
(poly{lactic-co-glycolic acid}), when released in a sustained manner to burn wounds, stimulated 
improved healing by reducing stress-related tissue damage, controlling inflammation, and 
enhancing tissue integrity. Ac
c
pte
d M
an
us
cr
pt
© 2015 The Author(s) Archiving permitted only in line with the archiving policy of Portland Press Limited. All other rights reserved.
Figure 1
A
D
B
C E
0
200
250
300
0 2 4 6 8 10 12 14 16 18 20
B
od
y 
W
ei
gh
t (
g)
F
Days Post Burn 
Ctrl Ins
*
* *
B
lo
od
 G
lu
co
se
 (m
g/
dl
)
G
Time after dressing application (hrs)
0
50
100
150
200
250
0 2 4 6 8 10
Ctrl Ins
Time Post Burn 
Skin B 12h 3D 6D 9D Healed
In
su
lin
 μl
U
/m
L
0
100
200
300
Placebo
Insulin
Normal Skin
** *** ***
H
Ac
ce
pte
d M
an
us
cri
pt
© 2015 The Author(s) Archiving permitted only in line with the archiving policy of Portland Press Limited. All other rights reserved.
Days Post Burn
0 3 6 9 12 15 18 21
(%
 A
re
a 
O
pe
n)
0
20
40
60
80
100 PlaceboInsulin
*** ***
**
B
D2
1 
   
   
D1
8 
   
   
 D
15
   
   
   
D1
2 
   
   
   
 D
9 
   
   
  D
6 
   
   
   
 D
3 
   
   
  D
0
A Placebo Insulin
Figure 2
Placebo Insulin
G H
K L
E F
C D
I J
Ac
ce
pte
d M
an
us
cri
pt
© 2015 The Author(s) Archiving permitted only in line with the archiving policy of Portland Press Limited. All other rights reserved.
Figure 3
A
12 24 48
0
5
10
15
20
25
Placebo
Insulin
N
eu
tro
ph
ils
/μm
2 X
10
-5
Hours Post Burn
**
**
C
FSC-A
0 50 K 100 K 150 K 200 K 250 K
250 K
200 K
50 K
0
100 K
150 K
FS
C
-A
FSC-H
0 50 K 100 K 150 K 200 K 250 K
Singlets
89.5
FSC-A
0 50 K 100 K 150 K 200 K 250 K
Cells
88.7
10 5
10 4
10 3
0C
om
p-
FI
TC
-A
-10 3
Comp-PE-A
-10 3 0 10 3 10 4 10 5
Q1
12.2
Q2
9.02
Q3
3.53
Q4
75.4
10 5
10 4
10 3
0C
om
p-
PE
-A
-10 3
Comp-APC-A
-10 3 0 10 3 10 4 10 5
CD163+  CD80- CD86-
14.1
250 K
200 K
150 K
100 K
50 K
0
FS
C
-A
Comp-APC-A
-10 3 0 10 3 10 4 10 5
CD80+  CD86+  163-
76.6
250 K
200 K
50 K
100 K
150 K
SS
C
-A
0
250 K
200 K
50 K
0
100 K
150 K
SS
C
-
A
B
1 2 3
5 64
M1 macrophages
Day Post Burn
3 6 9 12
%
 T
ot
al
 C
el
ls
0
10
20
30
40
50
Placebo
Insulin
**
*
M2 macrophages
Day Post Burn
3 6 9 12
%
 T
ot
al
 C
el
ls
0
2
4
6
8
10
Placebo
Insulin
**
*
*
D
Green - Myeloperoxidase
Ac
ce
pte
d M
an
us
cri
pt
© 2015 The Author(s) Archiving permitted only in line with the archiving policy of Portland Press Limited. All other rights reserved.
Figure 4
Day Post Burn
B 1 3 6 9 12
IL
-1
0 
(p
g/
m
l)
0
5
10
15
20
25
Placebo
Insulin
Normal Skin
*
*
Ac
ce
pte
d M
an
us
cri
pt
© 2015 The Author(s) Archiving permitted only in line with the archiving policy of Portland Press Limited. All other rights reserved.
Figure 5
Microvessels
0
1
2
3
4
V
es
se
ls
  p
er
 μm
2 X
10
-4
Number
**
0
2
4
6
8
10
12
14
W
id
th
 (μ
m
)
Width
0
2
4
6
8
10
12
14
Ar
ea
 (μ
m
2 )
Area
BA DC
Placebo
Insulin
E PBS InsulinF
VE-cad
GAPDH
H
PBS Insulin
VE-cadherin
In
cr
ea
se
 re
la
tiv
e 
to
 c
on
tro
l
0.0
0.5
1.0
1.5
2.0
I
Total Blood 
Vessel Length
To
ta
l b
lo
od
 v
es
se
l 
le
ng
th
 (m
m
) X
 1
0
0
2
4
6
8
10
G
***
*
Placebo
Insulin
Ac
ce
pte
d M
an
us
cri
pt
© 2015 The Author(s) Archiving permitted only in line with the archiving policy of Portland Press Limited. All other rights reserved.
Placebo Insulin
21
 d
ay
s 
po
st
 b
ur
n
Figure 6
C
B
Days Post Burn
1 2 3 6 9 12 17 21 24
H
yd
ro
xy
pr
ol
in
e
(u
g/
ul
)X
 1
0-
1
0
2
4
6
8
10
12
14
16
Placebo
Insulin
Normal Skin
***
***
**
A
B0
Ac
ce
pte
d M
an
us
cri
pt
© 2015 The Author(s) Archiving permitted only in line with the archiving policy of Portland Press Limited. All other rights reserved.
A4O2-.
H2O
H2O2SOD
H2O+ O2
. OH+HO-
Fe2+
Fe3+
NADPH 
Oxidase    
ONOO-
NONOS
Figure 7
Day Post Burn
B 1 2 3 6 9
H
2O
2
(μ
M
)
0
2
4
6
8
10
12
***
Placebo
Insulin
Normal Skin
**
Day Post Burn
B 1 2 3 6 9
G
P
x
A
ct
iv
ity
 
(n
m
ol
/m
in
/m
l) 
X 
10
2
0
1
2
3
4
Placebo
Insulin
Normal Skin***
E
C
Day Post Burn
B 1 2 3 6 9
S
O
D
 (U
/m
l) 
X
 1
01
5
10
15
20
25
30
Placebo
Insulin
Normal Skin
*
**
B
Day Post Burn
B 1 2 3 6 9C
AT
 a
ct
iv
ity
 (n
m
ol
/m
in
/m
l)
0
20
40
60
80
D
Placebo
Insulin
Normal Skin
*
Protein nitrosylation
Lipid peroxidation
Oxidative DNA damage
Ac
ce
pte
d M
an
us
cri
pt
© 2015 The Author(s) Archiving permitted only in line with the archiving policy of Portland Press Limited. All other rights reserved.
Figure 8
Day Post Burn
B 1 2 3 6 9
M
D
A 
(u
M
/m
g 
pr
ot
ei
n)
 X
 1
0-
1
0
2
4
6
8
10
A
Placebo
Insulin
Normal Skin
*
Day Post Burn
0 B 1 2 3 6 9
8O
H
dG
 p
g/
m
L 
X 
10
2
10
20
30
40
Placebo
Insulin
Normal Skin
***
*
*
Day Post Burn
B 1 2 3 6 9
N
itr
ot
yr
os
in
e
(n
M
) X
 1
01
0
2
4
6
8
10
12
14
**
Placebo
Insulin
Normal Skin
*
B
C
Ac
ce
pte
d M
an
us
cri
pt
© 2015 The Author(s) Archiving permitted only in line with the archiving policy of Portland Press Limited. All other rights reserved.
